Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 55,600 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president owned 56,862 shares of the company’s stock, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded up $0.44 during trading hours on Monday, hitting $190.46. The company’s stock had a trading volume of 725,871 shares, compared to its average volume of 1,139,928. The company has a 50 day moving average of $169.64 and a 200 day moving average of $151.92. The stock has a market cap of $11.72 billion, a PE ratio of -31.90, a price-to-earnings-growth ratio of 0.38 and a beta of 0.22. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $198.00. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.51 earnings per share. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently modified their holdings of JAZZ. Royal Bank of Canada lifted its stake in Jazz Pharmaceuticals by 96.5% during the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after acquiring an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares during the last quarter. Focus Partners Wealth increased its stake in shares of Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on JAZZ. Truist Financial upped their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Morgan Stanley raised their price target on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $214.57.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.